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Blepharocalyx salicifolius (Kunth) O. Berg (Myrtaceae) is a tree native to Argentina 
and Uruguay that grows and is cultivated along the riverside of the Rio de la Plata. 
The leaves of this plant species, locally known as “anacahuita” are used in South 
America to prepare infusions for the empiric treatment of cough and bronchospasm, 
as well as diarrhoea and other intestinal disorders. Although previous phytochemical 
studies have been performed with the essential oil extracted from Blepharocalyx 
salicifolius, pharmacological evidence supporting its traditional use is still lacking.  
Aim of the study: To experimentally evaluate the pharmacological properties of 
Blepharocalyx salicifolius based on its traditional use. The studies were performed 
with tincture (T-Bs) and essential oil (EO-Bs) prepared from its leaves, in isolated rat 
trachea, intestine and heart preparations. 
Methods 
The ex-vivo effects of T-Bs and EO-Bs were evaluated with the agonists carbachol 
(CCh) and calcium chloride (Ca
2+
) in the contractile concentration-response curves 
(CRC) of the isolated intestine. The muscle relaxant effect of EO-Bs was evaluated 
in the isolated trachea and compared with the effect achieved with papaverine as a 
positive control. The T-Bs and EO-Bs cardiac effects were analysed by perfusion of 
an isolated rat heart before a period of ischemia/reperfusion (stunning model). The 
antitussive effect of both T-Bs and EO-Bs was evaluated in mice exposed to 
ammonia using codeine as a positive control. 
Results 
Both T-Bs and EO-Bs induced a non-competitive inhibition of the CCh-CRC in the 
rat intestine, with IC50 values of 170.3  48.5 µg T-Bs/mL (n = 6) and 5.9  1.6 µg 
EO-Bs/mL (n= 6), respectively. EO-Bs also inhibited non-competitively the Ca
2+
-
CRC, with IC50 value of 1.8 ± 0.3 µg EO-Bs/mL (n= 8). A similar effect was 
obtained with the main active component of the EO-Bs 1,8-cineole. In isolated 
trachea, EO-Bs induced the relaxation of the CCh-contracted tissue (1.7 ± 0.2 µg 
EO-Bs/mL, n = 11) up to a maximal relaxation that was 1.9 times higher than that of 
papaverine. In the isolated heart, EO-Bs induced a poor negative inotropic response, 
and did not improve the contractile and energetic recovery after ischemia and 
reperfusion. In the mouse cough model, EO-Bs (90 mg/Kg) was as effective as 
codeine (30 mg/Kg) in reducing cough frequency. 
Conclusions 
The results indicate that the preparations from Blepharocalyx salicifolius leaves were 
effective as central antitussive, bronchodilating and antispasmodic agents, suggestive 
of a mechanism associated with the inhibition of Ca
2+
 influx into smooth muscle. 
The EO-Bs displayed only a poor ability to reduce cardiac inotropism, and was 
devoid of any cardioprotective properties. Thus, the present study validates the 
traditional use of this South American plant for asthma, cough and bronchospasm, 











: ionic calcium; CCh: carbachol; CRC: concentration response curve; EO-Bs: 
essential oil of Blepharocalyx salicifolius ; T-Bs: tincture of Blepharocalyx 
salicifolius; IC50: 50% inhibitory concentration ; EC50: 50% effective concentration  
; GC-FID-MS: gas chromatography with flame ionization and mass spectrometry 
detectors. 
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The aromatic tree Blepharocalyx salicifolius (Kunth) O. Berg (syn. B. 
tweediei (Hook. et Arn.) Berg, Myrtaceae) is a plant native to South America that 
grows near the riverside of the Rio de la Plata and its marginal jungle in Argentina, 
on the hills of Uruguay and southern Brazil, and even in sandy soils of these South 
American countries (Lahitte et al. 1999). The plant is known as “anacahuita”, which 
is a name derived from the Mexican nahuatl word “anatlquahuitl”, meaning “paper 
tree” assigned by similarity to a Mexican tree that is also used for the treatment of 
respiratory diseases (Lahitte et al. 1999). The leaves of Blepharocalyx salicifolius are 
used to alleviate cough, sore throat, bronchospasm, intestinal diarrhoea as well as 
other intestinal disorders (Ratera and Ratera, 1980). In Uruguay, either an infusion or 
an alcoholic extract prepared with the leaves and fruits of this plant are used as tonic 
to alleviate the symptoms of indigestion and cough (Alonso and Desmarchelier, 
2005). In southern Brazil, this plant is also used as external astringent in baths for the 
treatment of diarrhoea, leucorrhoea, urethritis and rectal prolapse (Mors et al. 2000), 
as antirheumatic and hypoglycemic agent (Alice et al. 1991), as diuretic and to treat 
stomach diseases (Moreira et al. 1999). 
The composition of the Blepharocalyx salicifolius essential oil (EO-Bs) 
varies among the regions where this species grows (Dellacasa et al. 1997; Tucker et 
al. 1993; Moreira et al. 1999; Limberger et al. 2001; Garneau et al. 2013), but  its 
main active component has recently been identified as 1,8-cineole (Garneau et al. 
2013). The active ingredient 1,8-cineole is also characteristic of the essential oil 
obtained from the leaves and fruits of Eucalyptus globulus; which is known to confer 
antiseptic and bronchodilating properties (Salari et al. 2006; Mulyaningsih et al. 
2010). The bronchodilating effect of 1,8-cineole is the basis of the efficacy in the 
cough treatment (Juergens et al. 2003; Coelho-de-Souza et al. 2005; Nascimento et 
al. 2009).  
Although a phytochemical characterization of the Blepharocalyx salicifolius 
essential oil has previously been carried out (Garneau et al. 2013), there are no 
reports describing the effects this plant has on respiratory and intestinal smooth 
muscle. The aim of this work was to evaluate the pharmacological effects of both the 
ethanolic extract or tincture (T-Bs) and the EO-Bs obtained from specimens growing 
in this region of the Country, on isolated rat trachea and small bowel preparations. 
Moreover, both the antitussive effect in mice, and the inotropic effect on isolated rat 
hearts of EO-Bs were also assessed and  mechanisms of action determined.  
  
2. Materials and Methods 
 
2.1. Plant material and extraction 
Leaves of Blepharocalyx salicifolius (Kunth) O. Berg (Myrtaceae) were 
collected around the field of the Facultad de Agricultura y Ciencias Forestales de la  
Universidad Nacional de La Plata (34º 52' S, 57° 54´ W) on December 2013, allowed 
to dry at room temperature for 4 weeks and identified as NDBAYON 1643 by MSc 
Agr Ing Marta Colares in the Herbarium de la Universidad Nacional de La Plata, 
according to Zuloaga et al. (2014). The EO-Bs was obtained by hydro-distillation 
using a Clevenger type apparatus according to Argentinean National Pharmacopoeia. 
For the biological studies, the EO-Bs was diluted in dimethylsulfoxide (DMSO). In 
some biological preparations, the tincture (T-Bs) prepared by maceration of leaves at 
10% in ethanol 70° (yield 26.3% w/w after evaporation of tincture to residue) was 
tested. The T-Bs was diluted in Tyrode solution on the day of the experiment, and its 
concentration was expressed as µg residue/mL.  
 
2.2. Analysis of the essential oil 
The analysis of EO-Bs was performed by gas chromatography with flame 
ionization detector and coupled to a mass spectrometry detector GC-FID-MS. A gas 
chromatograph Agilent 7890A series (Agilent Technologies, Santa Clara, CA, USA) 
equipped with a flame ionization detector (FID), split / split-less (split ratio 1:100) 
was used and interconnected to a mass detector 5975C (Agilent Technologies, Santa 
Clara, CA, USA). Data acquisition, processing and instrument control were 
performed using the Agilent ChemStation (Agilent Technologies, Santa Clara, CA, 
USA) software. The injector temperature was 250°C and FID temperature was 
260°C. A capillary column HP-WAX, 60 m x 0.25 mm ID and 0.25 µm thick film 
was used for the FID and a nonpolar capillary column HP-1, with the same 
characteristics for the detector mass (70 eV), they were used for quantization and 
determination of linear retention indices. The oven temperature was programmed 
identically for both columns, starting at 100°C to 240°C at 2°C/min and kept 
constant for 15 min Helium was used as gas carrier at a constant flow of 1.8 mL/min, 
injection volume was 0.3 µL, hydrogen (30 mL/min) and air (300 mL/min) were 
used in the FID with nitrogen (30 mL/min) as auxiliary gas. Temperatures for the 
transfer line and the ion source were set at 280ºC and 230°C, respectively. The mass 
range (m/z) was 40-500 Da. Compound identification was conducted by analyzing 
the lineal retention indexes (relative to C8–C24 n-alkanes) obtained in both columns 
and compared with those of either reference compounds, or compounds identified in 
chemically well-known essential oils and/or from bibliography (Babushok et al., 
2011). Additionally, each mass spectra obtained was compared to those from the 
literature libraries (Adams, 2007; Wiley/NIST, 2008) and mass spectra obtained 
from reference compounds. Relative percentage contribution of the compounds was 
calculated from the FID responses by a computerized integration assuming all of the 
response factors were 1. 
The density of EO-Bs was measured by means of a pycnometer at 20°C 
(AOAC, 1990). 
 
2.3. Pharmacological studies 
2.3.1. Animals 
The research was conducted on both adult male and female Sprague-Dawley 
rats (200-250 g) as well as 2-3 month-old Swiss albino female mice (25-30 g), 
following internationally accepted principles of laboratory animal use and care as 
established by US guidelines (NIH publication 85-23 revised in 1985) and principles 
in the Declaration of Helsinski. The protocols and procedures were approved by an 
ethical local committee of Facultad de Ciencias Exactas de la Universidad Nacional 
de La Plata by numbers 015-05-15 and D-01-15-16. 
 
2.3.2. Isolation of smooth muscles preparations and contractile measurements 
Sprague-Dawley rats (200-250 g) were subjected to a 12 h fasting with free 
access to water before experimentation. Animals were anesthetized by urethane 
(doses of 1.5 g/Kg) and then quickly sacrificed by opening the thorax. Depending on 
the experiment, either the duodenum and ileum (about 2 cm long), and/or trachea 
were excised. Intestinal portions were individually mounted in organ baths 
containing constantly oxygenated Tyrode solution (20 mL, pH 8.2) at 37ºC  
(Emendorfer et al. 2005; Ragone et al. 2007; Chen et al. 2012; Matera et al. 2016). 
The trachea was dissected into 0.5 cm length rings, individually mounted in an organ 
bath containing oxygenated 20 mL Krebs solution. All preparations were 
equilibrated for at least 45 min at 1g of pre-load. Intestinal tissues were connected to 
isometric transducers WPI (USA) and the signals from four preparations were 
simultaneously amplified by a 4-channel preamplifier (WPI, USA). Data were stored 
in a personal computer with Eagle software (USA). The contractility of two tracheal 
rings were simultaneously detected by PanLab MLT0210/A isometric transducers 
and recorded by a PowerLab 2/26 system with LabChart A/D program (AD 
Instruments, Australia).   
  
2.3.3. Concentration-response curves with carbachol in small bowel 
Concentration-response curves (CRC) of contractility to carbachol (CCh-
CRC) were conducted in each rat duodenum or ileum. Previous tests in our 
laboratory had demonstrated that the CRC of either intestinal portion behave 
similarly (data not shown). Tissues were stabilized for 45 min in Tyrode’s solution. 
Several CRC were conducted in the same preparation by cumulatively adding to the 
bath CCh (range 0.01 to 10 g/mL) up to maximal contraction, first in the absence 
(control condition), and then in the presence of vehicle (control-vehicle with DMSO 
at 0.1% for comparing the EO-Bs series, or ethanol 70° at 1% for comparing the T-
Bs series, respectively), followed by CCh with a sole sequentially increasing 
concentration of either EO-Bs, T-Bs or 1,8-cineole. The contractile effect of each 
CCh concentration was expressed as percentage of the maximal contractile response 
of the tissue obtained with the control of CCh-CRC. As positive control, the present 
CRC were compared with those obtained with verapamil assessed in our laboratory 
and previously reported (Blanco et al. 2013).  
   
 2.3.4. Concentration-response curves with CaCl2 in small bowel 










, first in the absence and then in the presence of each EO-Bs 
concentration. The contractile effect was expressed as percentage of the maximal 
response obtained in the control Ca
2+
-CRC. Each EO-Bs concentration was added 5 




 that remained 
throughout the CRC. As a positive control, a previously reported Ca
2+
-CRC in the 
presence of verapamil was used (Blanco et al. 2013). Also, the effect of 1,8-cineole, 




2.3.5. Pharmacological parameters of CRC 
From the CRC performed with CCh and Ca
2+
, the pEC50 (as –log EC50, in 
mol/L) of the agonist was calculated. Since tincture and essential oil were a mix of 
compounds, the affinity (pKB´) could not be calculated (Kenakin, 2014). The 50% 
inhibitory concentration (IC50) was calculated by interpolation at 50% effect of the 
individual inhibitory curves, that is, those obtained for each biological preparation by 
plotting the maximal agonist effects in the absence and the presence of the 
subsequent concentrations of the antagonist (T-Bs, EO-Bs or 1,8-cineole), as 
previously described (Consolini et al. 2011; Matera et al. 2012). IC50 values of EO-
Bs or 1,8-cineole were expressed as µg/mL after considering the respective density 
of the natural product. Similarly, the IC50 T-Bs values were expressed as µg 
residue/mL. 
 
2.3.6. Experiments on isolated trachea  
Rat tracheal rings were kept in chambers with 20 mL Krebs solution bubbled 
with 95% O2 and 5% CO2 at 37ºC, as described (Nascimento el al. 2009). EO-Bs 
concentration-relaxation curves were conducted on CCh 10 µg/mL pre-contracted 
tissues, and values compared with those obtained with papaverine as a positive 
control.  
 
2.3.7. Experiments on isolated rat hearts and the model of ischemia-reperfusion 
Adult Sprague-Dawley rats (200 a 250 g weight) of either sex were 
heparinised (non-fractioned heparine 2000 IU) before being anesthetized with 25% 
urethane (1.5 grams/Kg, via i.p.). Hearts were rapidly excised and perfused through 
the coronary arteries by the Langendorff method, as previously described (Consolini 
et al. 2007; Ragone and Consolini 2009). Control Krebs (C) was perfused with a 





. This flow was sufficient to develop an optimal maximal pressure development (P) 
without significant edema, as previously described (Ragone et al. 2015; Colareda et 
al. 2016). Atria were removed and spontaneous beating was stopped by applying 
pressure on the focus in the interventricular septum. A latex balloon was introduced 
in the left ventricle, connected to a Bentley DEL900 pressure transducer by a flexible 
cannula. While continuously perfused, the heart was introduced into the chamber of 
a custom-made flow calorimeter (Ponce-Hornos et al. 1982), which was closed and 
submerged in a bath kept at controlled temperature of 37.0 ± 0.01ºC. Rat hearts were 
electrically stimulated with 5 V-5 ms at 3 Hz, by means of two electrodes connected 
to an electrical stimulator (Letica LE12406, Spain). The isovolumic left 
intraventricular pressure (LVP) at optimal volume and the total heat rate (Ht) were 
simultaneously and continuously recorded in a PowerLab 2/26 two-channel digital 
acquisition system (AD Instruments, Australia). The maximal pressure developed 
over the diastolic level (P) during contractions, as well as the changes in diastolic 
pressure over the preischemic condition in Krebs-C (ΔLVEDP), were both calculated 
and expressed in mmHg.  
The calorimeter used in the present study has been previously described 
(Ponce-Hornos et al. 1982: Ponce-Hornos et al. 1995; Consolini et al. 2007). Briefly, 
the internal chamber has two ceramic modules with 127 thermosensitive units 
(Melchor Thermoelectrics) each, which detect changes in temperature between the 
inside (heart) and the outside (bath). Calibration details (in mW/mV) with a constant 
electrical power on the muscle at the end of the experiment and the calorimetrical 
base lines can be seen in previous publications (Consolini et al. 2001; Consolini et al. 
2007; Ragone et al. 2015). The calorimeter was submerged in a temperature-
controlled water bath, connected with two other baths, one used for regulation 
(Lauda, Germany) and the other one for heating the perfusates, thus buffering the 
temperature. The calorimetrical signal was measured before and after introducing the 
heart, in the presence and absence of perfusion, in order to obtain a baseline of the 
total heat signal in the presence of the heart. The total heat rate (Ht) was calculated 
from that difference between both signals, expressed in mW/g wet weight.  
The cardio-protective effect of EO-Bs was evaluated before exposing the 
heart to stunning by ischemia and reperfusion. An “initial control value” of P and Ht 
was recorded after an approximately 40 min stabilization period with Krebs-C 
solution, after which the heart was pretreated with or without (control group) T-Bs or 
EO-Bs. The heart was then exposed to a 20 min period of no-flow ischemia (I) 
followed by a 45 min reperfusion period (R) with Krebs solution without drugs. 
Heart contractility and heat release during I/R, were obtained, and expressed as 
percentage of either P or Ht steady initial value, respectively. Finally, muscle 
economy was calculated as the P/Ht ratio, as previously described (Ragone et al. 
2015; Colareda et al. 2016). 
In order to determine whether EO-Bs had an effect on sarcoplasmic reticulum 
Ca
2+
 release, a group of hearts was treated with 3 µmol/L ryanodine (Rya) as a 
selective blocker before EO-Bs perfusion. Further, in order to evaluate the role of the 
mitochondrial Na/Ca-exchanger (mNCX), before and during EO-Bs perfusion hearts 
were also perfused with the selective inhibitor clonazepam (Clzp, 10 µmol/L) as 
previously reported (Consolini et al. 2007; Ragone et al. 2013). 
 
2.3.8. Antitussive effect 
The antitussive effect of EO-Bs was investigated with a model of cough 
induced in live mice by ammonia liquor (Shang et al. 2010; Wang et al. 2012). 
Briefly, 30 min after intraperitoneal (i.p.) administration of EO-Bs, each mouse was 
placed in a 1000 mL special glass chamber and exposed to vaporization of 25% 
NH4OH (0.1 mL) for 60 seconds. Each mouse was continuously monitored by a 
trained observer during a 3 min period with the help of a stethoscope over the glass 
chamber. Cough was detected as a contraction of thoracic and abdominal muscles 
followed by the mouth opening with a coughing sound and jerking of the front body 
of the mouse. The frequency (number of coughing episodes in 3 min) and the latency 
time were counted. Groups of 8 mice each were assessed, including a negative 
control (10% DMSO), test solutions (EO-Bs at doses of 3, 10, 30 and 90 mg/Kg) and 
a positive control with codeine phosphate (30 mg/Kg). All doses were administrated 
via i.p in 0.1 mL/30 g body weight.  
 
2.3.9. Solutions and drugs 
The Tyrode solution used in intestinal tissue preparations had the following 
composition (in mmol/L): 150 NaCl, 2.7 KCl, 2 MgCl2, 12 NaHCO3, 0.4 PO4H2Na, 
1.8 CaCl2 (pH 8.2). The Ca-free (Tyrode’s-0Ca
2+
) was obtained by eliminating CaCl2 




by addition of 10% 
KCl (0.6 mL)  to 20 mL Tyrode’s 0Ca
2+
.  
The Krebs solution used for the tracheal rings, had the following composition 
(in mmol/L): 118.2 NaCl, 25 NaHCO3, 11.7 dextrose, 4.7 KCl, 2.5 CaCl2, 0.4 
KH2PO4, 1.2 MgSO4.7 H2O, bubbled with 95% O2-5% CO2.  
The Krebs-C solution used with the isolated heart preparation, had the 
following composition (in mmol/L): 1 MgCl2, 125 NaCl, 0.5 NaH2PO4, 7 KCl, 2 
CaCl2, 25 NaHCO3, and 6 dextrose, bubbled with 95% O2-5% CO2. 
The natural products obtained by EO-Bs hydro-distillation (density 0.9019 
g/mL) and the 1,8-cineole compound (density 0.9240 g/mL) were diluted in DMSO 
to 0.01% (90.19 µg/mL EO-Bs and 92.4 µg/mL 1,8-cineole) and then in water to 
reach the respective concentrations for addition to either the Tyrode or Krebs 
solutions. The effect of the DMSO (0.1% in Tyrode as maximal concentration) was 
also assessed in the CRC as a control-vehicle. Drugs employed in biological tests 
included: Carbamylcholine chloride (carbachol, CCh, Sigma, USA), papaverine 
chloride (Sigma, USA), ryanodine (Rya, Sigma, USA), clonazepam (Clzp, Saporiti, 
Argentina). CCh, papaverine, and Clzp were dissolved in water, and Rya, in DMSO. 
The CCh-CRC was obtained by cumulative addition of increasing 
concentrations of CCh between 0.01 and 10 µg/mL. The Ca
+2
-CRC was obtained by 
cumulative addition of increasing concentrations of CaCl2 to reach values ranging 




Tyrode´s solution. The EO-
Bs concentrations used were 0.1, 0.3, 1, 3 and 10 µL EO-Bs/mL in Tyrode’s 
solution, later expressed as µg EO-Bs/mL after considering the density. 
 
2.3.10. Statistical analysis 
All results are expressed as the mean ± SEM (n = number of tissue 
preparations in the ex vivo experiments, and of animals in the in vivo protocols). 
Statistical multiple comparisons were done by two-way ANOVA , as considering the 
two variables in the effect, namely the treatment and the x-axis variable, that is, the 
agonist concentration (as pCCh or pCa, in the CRC) or the time (in the cardiac I/R 
experiments). After ANOVA, the Bonferroni´s post hoc test was applied for 
comparing the effects of a given treatment with the respective effect in the control 
condition at each x-axis value. The one-way ANOVA was used for comparing more 
than two values of one variable (Figure 6), followed by Tukey´s post hoc tests. The 
Student’s t-test was also used whenever necessary for the comparison of  the effect 
elicited by either two treatments. Statistical analyses were conducted with Graph Pad 




3.1. Composition of the essential oil  
The essential oil yield was 1.2% (v/w as dried material), and the relative 
percentage composition of the EO-Bs is shown in Table 1. The main components are 
1,8-cineole (38.5%), limonene (13.1%), β-pinene (9.1%), α-pinene (5.2%), linalool 
(4.3%), terpinen-4-ol (2.6%), -terpineol (2.9%) and β-caryophyllene (2.3%). The 
density of EO-Bs was 0.9019 g/mL. 
 
3.2. Effects on carbachol CRC in small bowel 
The T-Bs (yield 26.3% w/w) inhibited the contractions of the control CCh-
CRC significantly at concentrations of 79 µg/mL T-Bs and higher (* P < 0.05 vs 
control, Fig. 1A), in a behavior typical of non-competitive antagonism, with an IC50 
value of 170.3  48.5 µg/mL T-Bs (n = 6 preparations from 2 animals). The EO-Bs 
also inhibited the control CCh-CRC as a non-competitive antagonist at 
concentrations of 0.9 µg/mL EO-Bs and higher (* P < 0.05 vs control, Fig. 1B), with 
an IC50 value of 5.9  1.6 µg/mL EO-Bs (n = 6 preparations from 2 animals). 
 
3.3. Effects on calcium CRC in small bowel 
To evaluate whether in the EO-Bs effect the inhibition of L-type channel-
mediated Ca
2+
 influx was implicated, both EO-Bs and its main component 1,8-
cineole were assessed on the Ca
2+
-CRC in Tyrode`s-40 mmol/L K
+
 solution. Both, 
EO-Bs and 1,8-cineole non-competitively blocked the Ca
2+
-CRC (EO-Bs 
significantly inhibited the maximal Ca
2+
 contraction at concentrations of  0.902 
µg/mL and higher. and 1,8-cineole did it at concentrations of 0.924 µg/mL and 
higher. * P < 0.05 vs control in Fig. 2 A and B, respectively). The IC50 values were 
1.77 ± 0.34 µg/mL (n = 8) for EO-Bs and 23.7 ± 5.5 µg/mL (n = 6) for 1,8-cineole, 
respectively.  
 
3.4. Effects on the isolated trachea 
The EO-Bs reduced the CCh-induced tonic contracture, with an IC50 value of 
1.68 ± 0.24 µg EO-Bs/mL (n = 11). As Figure 3 shows, the maximal relaxation was 
1.9 times higher than that obtained with papaverine, and the IC50 value was 10.5 
times lower than that observed with this drug (17.6 ± 2.8 µg/mL, n = 5).  
 
3.5. Effects on isolated hearts 
Sequential perfusion of T-Bs diluted to 0.002, 0.02 and 0.2 % w/v 
(respectively 5.26, 52.6 and 526 µg extract/mL) did not significantly change the 
isolated hearts inotropism (P) (Figure 4A). The subsequent exposure to 20 min of 
ischemia in the presence of 0.2% T-Bs and 45 min of reperfusion without T-Bs 
(model of stunning due to I/R) did not modify the post-ischemic contractile recovery 
(PICR as % of initial P, Figure 4A, 2-way ANOVA P = 0.86), but slightly increased 
the energetic output measured as heat flow (% of initial Ht, Figure 4B, 2-way 
ANOVA P = 0.06), and significantly reduced the total muscle economy (P/Ht) 
before and after I (Figure 4C, 2-way ANOVA P = 0.005). This loss of economy was 
in line with the increase in the diastolic tone during I/R (+49.8 ± 11.6 vs. +7.7 ± 1.9 
mmHg of treated vs. control hearts at 5 minutes R, and +41.3 ± 12.5 vs. +1.7 ± 0.6 
mmHg of treated vs. control groups at 45 minutes R, both n = 7 and P < 0.001 by 
unpaired t-test). A similar result was found when the preparation was perfused only 
with the lowest concentration of 0.002% T-Bs before I/R (results not shown). 
 EO-Bs perfusion at 0.0001% v/v (0.90 µg EO-Bs/mL) induced a marginal 
negative inotropism before I and slightly reduced the PICR (* P < 0.05 by post-test 
vs. control, Figure 5 A) without any change in Ht, so that it reduced the post-
ischemic contractile economy (P/Ht) (* P < 0.05 by post-test vs. control, Figure 5B). 
EO-Bs also induced an increase in the diastolic contracture (ΔLVEDP) during the 
entire I/R period, when compared with the control group (* P < 0.05 by post-test vs. 
control, Figure 5C). 
To assess whether the diastolic contracture was due to Ca
2+
 lost from 
mitochondria, hearts were pretreated with clonazepam (Clzp, 10 µmol/L) an 
inhibitor of the Ca
2+
 extrusion by the mitochondrial Na/Ca exchanger (mNCX), 
before and during perfusion with EO-Bs. Figure 5 shows that Clzp improved PICR 
and P/Ht respect to the EO-Bs effect alone (# P < 0.05 by post-test vs. EO-Bs, 
Figures 5A-B) during R, but it did not significantly reduce the increase in LVEDP 
elicited by EO-Bs (* P < 0.05 by post-test vs. control, Figure 5C). 
To evaluate whether the effect of EO-Bs on diastolic contracture was caused 
by Ca
2+
 release from sarcoplasmic reticulum (SR), the effect of  ryanodine (Rya, 3 
µmol/L), a selective blocker of the ryanodine receptor type 2 (RyR2), was tested 
before and during the perfusion of EO-Bs and exposure to I/R. As expected, Rya 
reduced P before I/R as well as the PICR and the recovery of P/Ht (* P < 0.01 by 
post-test vs. control and vs. EO-Bs, Figure 5A-B). However, Rya did not avoid 
diastolic contracture (* P < 0.05 by post-test vs. control, NS vs EO-Bs, Figure 5C), 




3.6. Antitussive effects of EO-Bs in mice 
 The i.p. administration of EO-Bs at doses of 3 and 10 mg/Kg did not induce 
any antitussive effects. Higher doses of 30 and 90 mg/Kg, however reduced the 
number of coughing episodes, being the highest dosage equipotent with the effect of 
codeine phosphate 30 mg/Kg (* P < 0.01 by post-test vs. control, Figure 6A). EO-Bs 
also had a tendency to increase the coughing latency time, although less than codeine 
(* P < 0.05 by post-test vs. control, Figure 6B).   
4- Discussion 
The present study describes the pharmacological effects of tincture (T) and 
essential oil (EO) obtained from dried leaves of Blepharocalyx salicifolius 
(“anacahuita”). Characterization of the essential oil of this plant species has already 
been determined elsewhere (Talenti et al. 1984; Tucker et al. 1993). Therefore, our 
aim was to expand on its bioactivity and possible mechanism(s) of action. To find 
out whether our products were in line with those characterized in previous studies, 
the composition of the volatile fraction used in the present pharmacological tests was 
first determined. The EO-Bs displayed a similar chromatographic profile than that 
reported by Talenti et al. (1984) and Tucker et al. (1993), who also worked with 
plant material obtained from Argentina, and found limonene and 1,8-cineole as the 
main constituents. Analyses carried out with plant material from other sources (e.g. 
Uruguay and Brazil) however, differ from our results (Dellacassa et al. 1997; 
Limberger et al. 2001; Furlán et al. 2002; Garneau et al. 2013; da Costa et al. 2014; 
Godinho et al. 2014). The differences in composition could be attributed to 
geographic and climatic factors prevailing in the places where the plant materials 
were obtained (Benomari et al. 2016). For these reasons, the chemical composition 
of the volatile fraction used in the pharmacological studies has always to be specified 
(Bandoni et al. 2009). 
The present results demonstrate that the traditional use of Blepharocalyx 
salicifolius to alleviate cough, bronchospasm and diarrhoea is based on the 
bronchodilator, antitussive and intestinal antispasmodic effects, respectively. We 
further determined that this species exerted a slight negative inotropic effect; 
although, no cardioprotective properties against ischemia and reperfusion were 
found.  
In the intestinal smooth muscle preparation, both T-Bs and EO-Bs inhibited 
contractility during the CCh-CRC in a non-competitive manner, with an IC50 value 
of about 170 µg T-Bs/mL and 5.9 µg EO-Bs/mL, respectively. To further study the 
mechanism implicated in the latter effect, EO-Bs was assessed on the Ca
2+
 CRC, and 
again found it as a non-competitive inhibitor (Fig. 2A). This effect may be mainly 
due to the presence of 1,8-cineole in EO-Bs, because a similar response was obtained 
with this purified compound (Fig. 2B). The IC50 value of EO-Bs (about 1.8 µg/mL) 
on Ca
2+
 CRC, was lower than that of 1,8-cineole (about 23.7 µg/mL), suggesting that 
other components could act synergistically with 1,8-cineole. This is in agreement 
with one of the phytopharmacological findings,in which complex mixtures such as 
an EO could be more potent than the isolated components (Williamson, 2001; 
Mulyaningsih et al. 2010). The pattern of the Ca
2+
 CRC non-competitive inhibition 
was found to be similar to that obtained with verapamil, a well known Ca
2+
 channels 
blocker, which had an IC50 value of 0.25 mg/mL in the Ca
2+
-CRC done in isolated 
intestine (Blanco et al. 2013). Verapamil is known to block L-type Ca
2+
 channels 
from the inside of the cell, in a site different from the Ca
2+
 binding one (Spedding, 
1985) thus explaining the non-competitive inhibition pattern. Both 1,8-cineole and 
EO-Bs showed the same typical behavior as non-competitive L-type Ca
2+
 channel 
blockers, with about 10 and 140 times higher potency than verapamil, respectively. 
This mechanism may also explain the muscle relaxant effect of 1,8-cineole in other 
smooth muscles such as bronchus (Nascimento et al. 2009).  
On rat isolated trachea, the results showed the relaxant effect of EO-Bs on 
respiratory smooth muscle, which may support the traditional use of the plant 
extracts on both asthma and bronchospasm. EO-Bs displayed a relaxant activity that 
was about twice more relaxant and 10 times more potent than papaverine, a well 
known phosphodiesterase inhibitor (Kaneda et al. 1998). The great efficacy found in 
the tracheal tissue was in line by the antitussive effect demonstrated in the in vivo 
coughing test in mice. The irritation test with ammonia vaporization showed that 
EO-Bs at 90 mg/Kg acts as a central antitussive, almost equivalent to 30 mg/Kg 
codeine phosphate.  
The fact that EO-Bs inhibited Ca
2+
 CRC  is consistent with a potential effect 
on calcium influx to the smooth muscle, and it suggested that this EO could have 
beneficial properties for the heart. The results in the moderate stunning isolated rat 
heart model showed that the perfusion of T-Bs at concentrations between 5.26 and 
526 µg/mL and EO-Bs at 0.90 µg/mL induced a slight negative inotropic effect 
before ischemia. Considering that 1,8-cineole is the most abundant component in 
EO-Bs, the results are in agreement with the work of Soares et al. (2005), in which 
1,8-cineole was found to induce negative inotropism in rat cardiac papillary muscle, 
in that case attributed to inhibition of Ca
2+
 influx. However, those properties were 
not responsible of cardioprotection in our model of moderate stunning, since neither 
T-Bs nor EO-Bs improved the contractile recovery during reperfusion. Cardiac 
energetic output, as assessed by heat release, remained unchanged after tissue 
treatment with EO-Bs; however, the total muscle economy (P/Ht) was reduced by 
both T-Bs and EO-Bs (Figures 4 and 5). Moreover, both T-Bs and EO-Bs induced 
diastolic contracture, considered as a caffeine-like effect (Bers 2001), which may 
account for the reduced muscle economy. To understand the cellular mechanism of 
this effect, the transporters that generally lead to a Ca
2+
 rise within the cytosol were 
selectively blocked, and the effects on the I/R event were evaluated. The SR Ca
2+
 
release was blocked by ryanodine (Bers, 2001), and the mitochondrial Ca
2+
 extrusion 
through the mNCX was inhibited by clonazepam (Clzp) (Cox and Matlib, 1993; 
Consolini et al. 2007). Despite Clzp partially improved contractility and economy 
(P/Ht) it did not reduce ΔLVEDP, suggesting that diastolic contracture was not due 
to mitochondrial Ca
2+
 extrusion through the mNCX. The increase in PICR could be 
explained by the consequently higher mitochondrial Ca
2+
 concentration, which 
activates metabolism enzymes and thus ATP and PCr synthesis (Gunter and Sheu, 
2009). On the other hand, we assessed whether the effects of T-Bs and EO-Bs 
(diastolic contracture with reduced economy) were due to activation of the RyR2 and 
hence Ca
2+
 release from the SR, as it was observed with caffeine (Bers, 2001). The 
effects of caffeine include a high energy consumption associated with Ca
2+
 removal 
(NCX) (Bonazzola et al. 1992) as well as those seen with EO-Bs. Nevertheless, the 
diastolic contracture elicited by the EO-Bs was not affected by the SERCA blocker 
ryanodine (Figure 5 C). Rya strongly reduced P, Ht and P/Ht, as a consequence of 
the low SR Ca
2+
 storage. It can be concluded that plant extracts from Blepharocalyx 
salicifolius did not induce Ca
2+
 release through the RyR2 as caffeine does. The 
results suggest that EO-Bs could be directly activating the actin-myosin interaction 
at myofilaments level. 
 
Conclusion 
This is the first pharmacological study which supports the traditional uses of 
leaves from Blepharocalyx salicifolius for respiratory diseases. Our results 
demonstrated that the EO-Bs is effective in the treatment of cough and 
bronchospasm. It was found to be more potent than papaverine in the 
bronchodilating effect, and as good an antitussive agent as codeine. The mechanism 
is at least in part likely associated with the inhibition of Ca
2+
 influx to the smooth 
muscle, a process in which the EO-Bs was also more potent than verapamil as an 
intestinal antispasmodic. Moreover, data from the present study provides evidences 
suggesting poor negative heart inotropism; which does not imply cardioprotection 
upon ischemia and reperfusion. Regarding the composition, the assessed EO-Bs had 
the same main components than those described for other samples of essential oil of 
Argentinean origin, that is 38% of 1,8-cineole and 13% of limonene. The compound 
1,8-cineole showed an antispasmodic effect in the intestinal smooth muscle and a 
similar mechanism than that of the EO-Bs, suggesting that it is the main compound 
responsible of the observed pharmacological effects.   
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Figure 1: Effects of tincture (T-Bs, A) and essential oil (EO-Bs, B) from 
Blepharocalyx salicifolius on the CRC of carbachol in small intestine. Results are 
shown as media and SEM (n = 6 in A and B). Two-way ANOVA´s: by treatment: P 
< 0.0001; and by log [CCh]: P < 0.0001 in both (A) and (B). Post-tests: * P < 0.05 
vs. control.  
 
Figure 2:  Effects of EO-Bs (A) and 1,8-cineole (B) on the Ca
2+
-CRC obtained in 
isolated rat intestine in a depolarizing media (both n = 8). Results are shown as 
media and SEM. Two-way ANOVA´s: by treatment: P < 0.0001 and by log [Ca
2+
]: 
P < 0.0001 in both, (A) and (B). Post-tests: *P < 0.001 vs. control.  
 
Figure 3: Concentration–response curves of EO-Bs (IC50 = 1.68 ± 0.24 µg/mL, n = 
11) and papaverine (IC50 = 17.6 ± 2.8 µg/mL, n = 5) on isolated rat trachea pre-
contracted by 10 µg/mL carbachol (CCh). Relaxation was calculated as percentage 
of the maximal CCh contraction. Results are shown as media and SEM. Note that 
IC50 value (at 50% of the maximal CCh contraction) of EO-Bs was about 10.5 times 
lower and that maximal relaxation of EO-Bs was 1.9 times bigger than those of 
papaverine.  
 
Figure 4: Changes in maximal pressure development of contraction (P as % of 
initial) (A), total heat rate (Ht as %) (B) and muscle economy (P/Ht) (C) of isolated 
rat hearts exposed to perfusion of the Blepharocalyx salicifolius tincture (T-Bs) 
sequentially at 0.002%, 0.02% and 0.2% before the ischemia and reperfusion (I/R) 
periods (n = 7) in comparison with the non treated hearts (control, n = 7) in the 
model of stunning due to I/R. Results are shown as media and SEM. Two-way 
ANOVA: by treatment: P = 0.38 (A), P = 0.065 (B) and P = 0.005 (C); by time: all P 
< 0.0001.  
 
Figure 5: Changes in contractility as maximal pressure development P (as % of 
initial) (A), in muscle economy P/Ht (B) and in diastolic contracture evoked over the 
initial, ΔLVEDP in mmHg (C) of isolated rat hearts before and during I/R (control, n 
= 7) and after perfusion of the essential oil (EO-Bs at 0.0001% or 0.9 µg/mL, n = 5) 
in the absence and the presence of 10 µmol/L clonazepam (Clzp, n = 6) or 3 µmol/L 
ryanodine (Rya, n = 6). Results are shown as media and SEM. Two-way ANOVA: 
by treatment: all P < 0.0001; by time: all P < 0.0001. Post-tests: *P < 0.001 vs. 
control, # P < 0.05 vs. EO-Bs.  
 
Figure 6: Effects of EO-Bs 3, 10, 30 and 90 mg/Kg on the number of cough episodes 
within 3 minutes (A) and on the latency time for cough (B) after misting ammonia 
liquor on mice. Control group mice were treated with 10% DMSO, and codeine 
phosphate (30 mg/Kg) was injected via i.p. for the positive control group (n = 7-9). 
Results are shown as media and SEM. One-way ANOVA: P < 0.05 in A and B. 
Post-tests: *P < 0.05, **P < 0.01, compared with control.  
 
  
Table 1. Relative percentage composition of the essential oils obtained from 














(E)-2-Hexenal# 826 827* 1240 1216* Tr 
Amyl acetate# 873 895** 1167 1177** Tr 
Bornilene ## 911 908** 1017 - Tr 
-Thujene 926 926* 1036 1027* 0.1 
-Pinene # 935 935* 1043 1025* 5.2 
-Fenchene 950 945* 1089 1061* 0.2 
Camphene # 951 947* 1100 1069* 0.5 
Myrcene # 974 983* 1170 1161* 0.6 
-Pinene # 979 973* 1133 1110* 9.1 
Isoamyl isobutanoate 996 1000** 1194 1190** Tr 
2-Methylbutyl isobutanoate 1001 1001** 1198 1203** Tr 
-Phellandrene # 1005 999* 1191 1168* 0.3 
-3-Carene 1011 1007* 1175 1147* Tr 
-Terpinene # 1012 1011* 1206 1176* 0.5 
p-Cymene # 1018 1015* 1286 1270* 1.3 
(Z)--Ocimene 1020 1029* 1235 1235* 0.1 
1,8-Cineole # 1022 1022* 1234 1211* 38.5 
Limonene # 1024 1024* 1221 1198* 13.1 
Acetophenone #  1036 1042* 1668 1648* 0.1 
-Terpinene # 1047 1050* 1264 1245* 1.1 
cis-Oxide linalool (Furanoid) 1056 1065* 1481 1446* 0.1 
trans-Oxide linalool (Furanoid) 1072 1072* 1452 1454* 0.1 
Linalool # 1081 1086* 1549 1543* 4.3 
Terpinolene 1082 1079* 1305 1282* 0.5 
2-Methylbutyl 2-methyl butanoate 1086 1090** 1280 1286** 0.1 
α-endo-Fenchol 1103 1101* 1591 1570* 0.3 
Camphor # 1125 1125* 1541 1515* Tr 
trans Sabinol 1131 1131* 1727 1717* Tr 
Camphene hydrate 1138 1136* 1605 1602* 0.1 
Borneol # 1150 1153* 1711 1700* 0.8 
Terpinen-4-ol # 1164 1165* 1614 1601* 2.6 
-Terpineol # 1172 1176* 1705 1694* 2.9 
Myrtenol 1181 1194* 1796 1790* 0.1 
cis-Carveol 1208 1206* 1869 1854* Tr 
Carvone # 1215 1218* 1745 1734* Tr 
Geraniol # 1231 1239* 1852 1839* Tr 
bornyl acetate 1271 1270* 1601 1579* 0.3 
Alcohol Perilla 1281 1282* 2007 2007* Tr 
Thymol sym 1288 1304*** 2288 2287** 0.1 
exo-2-Hidroxycineole acetate ## 1324 - ? - 0.3 
Neryl acetate # 1340 1344* 1729 1718* 0.2 
Geranyl acetate # 1359 1361* 1760 1751* 0.3 
Methyl Eugenol # 1368 1376* 2019 2006* 0.1 
-Ylangene 1373 1370* 1500 1484* 0.1 
-Copaene 1376 1376* 1511 1491* 0.1 
-Elemene 1387 1388* 1603 1591* 0.1 
-Gurjunene 1410 1406* 1548 1529* 0.1 
-Caryophyllene # 1417 1419* 1614 1599* 2.3 
Aromandendrene 1437 1439* 1622 1620* 0.2 
-Humulene 1449 1449* 1683 1667* 0.7 
Alloaromadendrene 1456 1459* 1658 1649* 0.1 
cis-Cadina-1(6),4-diene ## 1467 - ? - 0.1 
-Muurolene     1468 1473* 1699 1690* 0.3 
α-amorphene 1473 1466* 1700 1693* 0.2 
trans-Cadina-1(6),4-diene ## 1473 - ? - 0.1 
-Selinene 1480 1481* 1732 1717* 0.5 
-Selinene 1489 1490* 1736 1725* 0.5 
-Muurolene 1492 1491* 1730 1723* 0.2 
-Cadinene 1504 1506* 1766 1763* 0.2 
cis-Calamenene 1508 1510* 1841 1835* 0.1 
-Cadinene 1512 1514* 1763 1755* 0.9 
-Calacorene 1525 1530* 1922 1921* 0.2 
-Cadinene 1528 1527* 1798 1769* 0.1 
Selina-3,7(11)-diene 1535 1538* 1789 1783* 0.8 
Germacrene B 1550 1535* 1836 1824* 0.1 
Spathulenol 1558 1566* 2125 2127* 0.2 
Caryophyllene oxide iso ## 1563 - 1977 2000** tr 
Caryophyllene oxide 1565 1570* 1989 1986* 0.5 
Guaiol 1581 1589* 2090 2089* 0.1 
Rosifoliol 1593 1599** 2123 2144** tr 
1-10-diepi-Cubenol  1602 1606* 2056 2074* 0.1 
1-epi-Cubenol 1614 1614* 2064 2088* 0.2 
-Eudesmol 1614 1617* 2170 2176* 0.2 
-Cadinol 1620 1626* 2171 2170* 0.6 
-Eudesmol 1629 1634* 2230 2238* 0.6 
Cubenol 1632 1620* 2056 2068* tr 
-Eudesmol 1636 1641* 2222 2223* 0.5 
TOTAL     94.9 
Aliphatic hydrocarbons  0.1 %    
Non oxigenated monoterpenes  32.6 %    
Oxygenated monoterpenes  50.9 %    
Non oxygenated sesquiterpenes  8.0 %    
Oxygenated sesquiterpenes  3.0 %    
 Others  0.3 %     
#: identified by two LRI, MS and standard comparison. ##: tentatively identified by one LRI and MS. 
All the other constituents were identified by two LRI and MS. LRI HP-1: experimental linear 
retention indices in the non-polar column. LRI HP-WAX: experimental linear retention indices in the 
polar column. tr: less than 0.05%. Compounds listed in order of elution in the non polar column. 
a
: 
LRI in similar non polar column from bibliography (*: Babushok et al., 2011; **: Wiley/NIST, 2008; 
***: Benomari et al., 2016). 
b
: LRI in similar polar column from bibliography (the same references) 










































































Table A.1: Results of 2-way ANOVA obtained from data in Figure 1, parts A and B. 










Table A.2: Results of 2-way ANOVA 
obtained from data in Figure 2, parts A and B. The results of Bonferroni´s “a posteriori” 
tests are shown in the respective figures. 
Variables of 2-
way ANOVA 
Fig. 1 A 
T-Bs 




F = 32.93 
DFn = 4 
P <0.0001 
F = 186.5 
DFn = 6 
P < 0.0001 
By log [CCh] F = 53.09 
DFn = 7 
P < 0.0001 
F = 202.7 
DFn = 7 
P < 0.0001 
Interaction  F= 1.873 




P < 0.0001 












Table A.4: Results of 2-way ANOVA obtained from data in Figure 4, parts A, B and C. 
The results of Bonferroni´s “a posteriori” tests are shown in the respective figures. 
Variables of 2-
way ANOVA 
Fig. 2 A 
EO-Bs 




F = 70.45 
DFn = 5 
P <0.0001 
F = 153 
DFn = 6 
P < 0.0001 
By log [Ca
2+
] F = 81.58 
DFn = 7 
P < 0.0001 
F = 571 
DFn = 6 
P < 0.0001 
Interaction  F= 6.066 
DFn = 35 
P < 0.0001 
F= 21.67 
DFn= 36 
P < 0.0001 











F = 0.0498 
DFn = 1 
P = 0.8235 
F = 3.405 
DFn = 1 
P = 0.065  
F = 7.968 
DFn = 1 










Table A.5: Results of 2-way ANOVA obtained from data in Figure 5, parts A, B and C. 
The results of Bonferroni´s “a posteriori” tests are shown in the respective figures. 
By time F = 83.04 
DFn = 32 
P < 0.0001 
F = 26.26 
DFn = 32 
P < 0.0001 
F = 13.71 
DFn = 32 
P<0.0001 
Interaction  F= 1.297 



















F = 568.5 
DFn = 3 
P < 0.0001 
F = 170.2 
DFn = 3 
P < 0.0001 
F = 137.8 
DFn = 3 
P < 0.0001 
By time F = 303.6 
DFn = 26 
P < 0.0001 
F = 51.48 
DFn = 26 
P < 0.0001 
F = 71.16 
DFn = 3 











Table A.6: Results of 1-way ANOVA obtained from data in Figure 6. part A and B. The 
results of Tukey´s “a posteriori” tests are shown in the respective figures. 
Interaction  F= 19.3 
DFn = 78 
P < 0.0001 
F= 4.872 
DFn= 78 
P < 0.0001 
F= 7.208 
DFn= 9 
P < 0.0001 
DF residual 540 540 80 
Variables of 1-
way ANOVA 








F = 21.39 
DF = 5 
P <0.0001 
F = 17.1 
DF = 5 












DF residual 40 40 
